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EscapeNatural killer (NK) cells play a critical role in host defense against viral infections. However chronic HIV-1
infection is associated with an accumulation of dysfunctional NK cells, that poorly control viral replication.
The underlying mechanisms for this NK cell mediated dysfunction are not understood. Certain tumors evade
NK cell mediated detection by dampening NK cell activity through the downregulation of NKG2D, via the
release of soluble NKG2D-ligands, resulting in a potent suppression of NK cell function. Here we show that
chronic HIV-1 infection is associated with a speciﬁc defect in NKG2D-mediated NK cell activation, due to
reduced expression and transcription of NKG2D. Reduced NKG2D expression was associated with elevated
levels of the soluble form of the NKG2D-ligand, MICA, in patient sera, likely released by HIV+CD4+ T cells.
Thus, like tumors, HIV-1 may indirectly suppress NK cell recognition of HIV-1-infected CD4+ T cells by
enhancing NKG2D-ligand secretion into the serum resulting in a profound impairment of NK cell function.T, and Harvard, Massachusetts
SA. Fax: +1 617 726 5411.
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Natural killer (NK) cells play a critical role in the host's ﬁrst line
defense against tumors and viral infections (Trinchieri, 1989).
Although these cells only constitute a small fraction of circulating
lymphocytes, NK cells are capable of rapidly destroying infected or
malignant cells without the need for prior antigen sensitization
(Kiessling et al., 1975). NK cells do not express an antigen speciﬁc
receptor, as do other lymphocytes. Instead, NK cells encode a variety
of different activating and inhibitory receptors, belonging to several
different receptor families (Lanier, 2005). Thus, NK cell activation is
dependent on a delicate balance of stimulatory and inhibitory signals
elicited by the multiple NK cell receptor–ligand interactions that take
place following NK cell–target cell interaction (Lanier, 2005).
One of the most potent activating NK cell receptors is NKG2D; a
homodimeric, C-type, lectin like, type II transmembrane receptor
encoded within the NK gene complex on Chromosome 12 (Bauer et al.,
1999; Lanier, 2005; Raulet, 2003). In humans, NKG2D is expressed on
most NK cells, CD8-T cells and γδT cells (Bauer et al., 1999; Raulet, 2003).
The activating signal triggered by the NKG2D-ligand-complex is one ofthe few dominant activating signals, as it can override inhibitory signals
(Diefenbach et al., 2001). A prerequisite of NKG2D-mediated killing is the
interaction of NKG2D with one of its numerous ligands. NKG2D ligands
are not expressed by healthy tissues but have been demonstrated to be
induced upon cell stress due to heat shock, viral infection, or malignant
transformation (Baueret al., 1999;Raulet, 2003).Among thesemolecules,
human NKG2D ligands include MHC class I-related chain (MIC) A and B,
and several UL-16 binding proteins (ULBP-1, 2, 3 and 4) (Cao et al., 2008;
Groh et al., 1996, 2001).
NKG2D-dependentNK cell cytotoxicity has been shown to be critical
in the control and clearance of several viral infections (Biron et al., 1989;
Etzioni et al., 2005; Fang et al., 2008). Furthermore, several viruses have
evolved to encode NKG2D-ligand homologues in order to subvert the
immunological pressure exerted by this strong activating receptor
(Arase et al., 2002). NKG2D and its ligands have been strongly
implicated in tumor immuno-surveillance (Lanier, 2001; Li et al.,
2009; Salih et al., 2003; Smyth et al., 2004; Vetter et al., 2002). While
NKG2D is a well conservedmolecule, its ligands are highly polymorphic
(Cao et al., 2008; Diefenbach et al., 2001; Groh et al., 1996; Lanier, 2005)
and have been associatedwith differential disease outcome in a number
of neurological, autoimmune, infectious disease and cancer models
(Fdez-Morera et al., 2006;Gambelungheet al., 2007; Lopez-Arbesuet al.,
2007; Shirts et al., 2007). In addition, in a recently published genome
wide association study, a single-nucleotide polymorphism in the MICB
gene has now been linked to AIDS-non progression (Limou et al., 2009).
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NKG2D through proteolytic shedding of NKG2D-ligands (NKG2D-L)
from the surface of target cells. NKG2DLs are enzymatically cleaved
from the surface of tumor cells releasing large concentrations of
NKG2DL into the extracellular milieu (Kaiser et al., 2007; Salih et al.,
2002; Waldhauer et al., 2008). NKG2D is rapidly internalized
following engagement with ligands, rendering NK cells temporarily
refractory to stimulation. Thus, elevated levels of soluble NKG2DLs in
the peripheral circulation can interact with NK cells at a distance from
the tumor, resulting in NKG2D downregulation and the generation of
anergized NK cells (Groh et al., 2002; Jinushi et al., 2008; Salih et al.,
2002). Typically, high levels of secreted NKG2DL are present in the
sera of particular cancer patients but not in healthy subjects (Jinushi
et al., 2008; Kaiser et al., 2007), and are associated with the
inactivation of NK cells via NKG2D, thus indirectly protecting these
tumor cells from direct elimination by NK cells that circulate in their
vicinity (Jinushi et al., 2008; Kaiser et al., 2007; Waldhauer et al.,
2008). Similarly, NK cell function becomes progressively dysfunction-
al during chronic HIV-1 infection, however the role of NKG2D/
NKG2DLs in this dysfunction has not been addressed.
Several classes of proteolytic enzymes have been implicated in
NKG2DL shedding including the endoplasmic reticulum protein 5
(ERP5) and the matrix metalloproteinases (MMPs) (Kaiser et al.,
2007; Salih et al., 2002). The MMPs, also designated matrixins, which
hydrolyze components of the extracellular matrix, play a central role
in many biological processes, and have been implicated in both
normal and pathological tissue remodeling, as well as inﬂammatory
responses (Hijova, 2005). Several reports suggest that progressive
HIV-1 infection is associated with elevated production and secretion
of MMPs, which may contribute to infection-associated immunopa-
thology, dysfunctional T cell responses, and dysregulated myeloid cell
trafﬁcking (Dezube et al., 2006; Ramankulov et al., 2008;Webster and
Crowe, 2006; Yokoyama et al., 2008). However, changes in MMP
expression in HIV-infected CD4+ T cells have not yet been assessed,
nor has their role in NKG2DL secretion. Here we show data
demonstrating reduced NKG2D expression on NK cells strongly linked
to the level of ex vivo NK cell activation. Alterations in NKG2D ex-
pressionwere furthermore associatedwith aberrant NKG2Dmediated
recognition of target cells, related to elevated secretion of the
NKG2DL, MICA, into patient sera. These data suggest for the ﬁrst
time, that active HIV-1 replication may subvert NK cells indirectly by
driving NK cell dysfunction via the cleavage and release of NKG2DL
into the peripheral circulation.
Results
Altered NKG2D expression on NK cells during chronic untreated HIV-1
infection
NKG2D is expressed on almost all NK cells in healthy individuals,
and is crucial for optimal NK cell mediated clearance of some virally
infected cells (Biron et al., 1989; Etzioni et al., 2005). While a small
number of studies have examined NKG2D expression on NK cells in
chronically infected patient populations (Mavilio et al., 2003), less is
known about the expression pattern of this critical activating receptor
on NK cell populations in spontaneous controllers and non-controllers
on or off antiretroviral therapy. Here we analyzed changes in surface
expression of the receptor NKG2D on NK cells in HIV-1 infected
individuals compared to healthy controls. The frequency of NKG2D+
NK cells was reduced in all HIV-infected individuals compared to
healthy controls (Fig. 1A). However, the percentage of NK cells
expressing NKG2D was most noticeably reduced on the surface of NK
cells from chronically infected individuals with active viral replication
in the absence of antiretroviral therapy compared to uninfected
controls or individuals that spontaneously control HIV-1 replication in
vivo (p=0.0001 and p=0.008, respectively, Fig. 1A). Furthermore,viral suppression in the presence of antiretroviral therapy was
associated with a slight but non-signiﬁcant increase in the frequency
of NKG2D+ NK cells compared to untreated subjects; however the
NKG2D+ NK cell density remained signiﬁcantly lower than those
observed in uninfected controls (p=0.03, Fig. 1A). Furthermore,
despite the fact that signiﬁcant changes were observed in the
frequency of NKG2D expressing NK cells in different HIV-infected
populations, no relationship was observed between NKG2D expres-
sion and clinical parameters including CD4+ T cell count or viral load,
nor with an elevation of CD56neg NK cells (data not shown),
suggesting that other immunological phenomena may drive reduced
expression of NKG2D on the surface of NK cells.
To determine whether these changes in surface expression were
paralleled by changes in NKG2D transcription, we compared NKG2D
transcript levels in bulk puriﬁed NK cells isolated from the different
clinical subgroups. NKG2D transcriptional levels were signiﬁcantly
reduced in untreated HIV-1 infected subjects compared to uninfected
controls (p=0.0029, Fig. 1B). Interestingly, the level of NKG2D
transcription was elevated in HIV-1 infected individuals on antire-
troviral therapy compared to HIV-1-uninfected controls (p=0.0136),
suggesting that viral suppressionwith antiretroviral therapy results in
a compensatory reconstitution of NKG2D transcription, but incom-
plete NKG2D protein expression on the surface of NK cells (Fig. 1A).
Similarly, HIV-1 controllers exhibited enhanced transcription of
NKG2D compared to chronic untreated individuals (p=0.0004,
Fig. 1B) associated with a higher frequency of NKG2D expressing NK
cells (Fig. 1A), indicating durable viral control is associated with
normal NKG2D transcription and surface expression. Overall, chronic
progressive HIV-1 infection is associated with a loss of NKG2D
expression and transcription.
Compromised NKG2D-dependent NK cell responses in chronic untreated
HIV-1 infection
Chronic HIV-1 infection is associated with an accumulation of
anergic NK cells (Alter et al., 2005; Mavilio et al., 2005). Given the
protective nature of NKG2D in other viral models, we sought to
investigate whether speciﬁc changes occurred in the quality of
NKG2D-dependent NK cell responses following HIV-1 infection. NK
cell degranulation (CD107a-upregulation) and activation (CD69-
upregulation) following stimulation with MHC class 1 target cells
were compared among HIV-1 infected individuals and uninfected
controls. Two different MHC class 1 target cell lines were employed
for these experiments, 221 cells, a MHC class 1 devoid B lympho-
blastoid cell line that induces natural cytotoxicity receptor (NCR)
mediated activation of NK cells, and K562 cells, an MHC deﬁcient
human erythromyeloblastoid leukemia cell line, that activates NK
cells in an NKG2D-dependent manner (Lozzio and Lozzio, 1977;
Shimizu and DeMars, 1989). Following stimulation, NK cell activation
(quantiﬁed by CD69-upregulation) was signiﬁcantly reduced in HIV-1
infected individuals in response to both cell lines (Figs. 2B and C),
however NK cell degranulation was only compromised following
stimulation with K562 cells (Fig. 2C). These data suggest that while
overall NK cell activation is dysregulated in HIV infection, a speciﬁc
dysfunction exists within the NK cell mediated NKG2D-induced
degranulation pathway during HIV-1 infection.
To determine whether suppression of viral replication to unde-
tectable levels by antiretroviral therapy can restore the observed
defect in the NKG2D-dependent activation of NK cells, we compared
NK cell activation and degranulation in response to K562 and 221 cells
in both treated and untreated HIV-1-infected individuals compared to
spontaneous controllers and HIV-1 negative controls. Little difference
was observed in the NK cell response to 221 cells among the clinical
groups (Fig. 2B), suggesting that the NCR pathway appears to be
relatively spared from dysfunction during chronic HIV-1 infection.
However, subjects with progressive chronic HIV infection exhibited a
Fig. 1. Reduced expression of NKG2D on NK cells in HIV infection. NKG2D expression was compared among individuals with chronic untreated (triangles, n=10), chronic treated
(squares, n=6), HIV controllers (transparent circles, n=10), and HIV-negative controls (ﬁlled circles, n=9) (A). Similarly, NKG2D transcription was compared among the same
groups of individuals (B).
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cells (Fig. 2C). In contrast, both spontaneous controllers, who
maintain low viral loads, and treated chronics degranulated slightly
less efﬁciently than HIV-negative controls, suggesting that active viral
replication at higher levels is required for the induction of dysfunc-
tional NK cell activity in response to K562 cells. Interestingly, NK cells
from both the treated and untreated chronic patients were poorly
activated in response to this NKG2D-activating cell line (Fig. 2C).
These data suggest that NKG2D-dependent NK cell degranulation can
only be partially reconstituted by highly active antiretroviral therapy.
Dysregulation of NKG2D down-modulation in HIV-1 infected individuals
Following NK cell stimulation, many activating receptors are
downregulated to avoid activation induced cell death (Huard and
Karlsson, 2000; Linsley et al., 1993; Valitutti et al., 1997). Along these
lines, NKG2D is downmodulated from the surface of NK cells following
stimulation with one of its ligands (Groh et al., 2002; Wiemann et al.,
2005). Thus, a functional NK cell downregulates NKG2D following
stimulation as a normal homeostatic mechanism to prevent activation
induced cell death, and serves as a marker of functional activation via
NKG2D. Given the critical nature of NKG2D to prevent cell death, we
sought to determine whether HIV infection resulted in any change in
the capacity of NK cells to downregulate this activating receptor from
the surface of activated NK cells. Thus we compared the mean
ﬂuorescence intensity (MFI) change in NKG2D-expression on degra-
nulating versus non-degranulating NK cells after stimulation with
K562 cells among the different infected populations. As anticipated,
NK cells from HIV-1 negative controls and controllers downregulated
NKG2D effectively following stimulation with K562, and therefore
displayed a high difference (Δ) in NKG2D expression following
stimulation (Fig. 3). In contrast, signiﬁcantly less NKG2D was lost on
NK cells derived from treated HIV progressive patients and there was
a trend towards a reduced NKG2D-loss in untreated chronically
infected patient compared to uninfected controls (p=0.02 and
p=0.06, respectively), resulting in lower differences (Δ) in NKG2D
expression (Fig. 3). However, both treated and untreated chronic
patients exhibited reduced NKG2D losses compared to NK cells from
HIV controllers (p=0.01 and p=0.05, respectively) suggesting that
NK cells in progressive infection lose the capacity to downregulateNKG2D, potentially due to the fact that they express low levels of this
molecule to begin as well as additional defects that may prevent
homeostatic protection from apoptosis. Thus chronic HIV-1 infection
is associated with an overall defect in NKG2D activation and
homeostatic regulation.
Chronic HIV-1 infection is associated with elevated levels of soluble
NKG2D-ligand, MICA, in patient sera
As reported previously, some tumors have evolved mechanisms to
evade NKG2D-mediated NK cell elimination, such as the release of the
soluble NKG2D-ligand, MHC class 1 related protein A (Groh et al.,
2002; Salih et al., 2003; Waldhauer et al., 2008). Soluble MICA
(sMICA) can inactivate NKG2D expressing NK cells at a distance,
resulting in a downregulation of NKG2D expression on NK cells
thereby preventing NK cells from recognizing and eliminating MICA
expressing tumor cells. To determine whether differences in sMICA
may account for the dysregulation of the NKG2D-pathway in HIV-1
infected individuals, we compared sMICA in the sera of HIV-1 infected
and uninfected individuals, including HIV-1 controllers. sMICA levels
were signiﬁcantly higher in untreated, chronically infected indivi-
duals compared to healthy controls and HIV-1 controllers (p=0.02
and p=0.002, respectively Fig. 4A). While treated chronics only
tended to have higher levels of sMICA in their peripheral circulation
compared to HIV-negative controls (p=0.2), they exhibited signiﬁ-
cantly higher levels of sMICA in serum compared to HIV controllers
(p=0.014), suggesting that therapeutic reduction of active viral
replication may not completely shut downMICA secretion potentially
resulting in persistently compromised NK cell activity. Thus, chronic
HIV-1 infection is associated with elevated levels of MICA in patient
sera that may represent a novel evasion strategy employed by HIV-1
to subvert detection by NKG2D-expressing NK cells.
Elevated levels of sMICA result in impaired NKG2D downregulation
As mentioned above, in healthy individuals, NKG2D is down-
regulated from the surface of NK cells following stimulation with one
of its ligands (Groh et al., 2002; Wiemann et al., 2005). As a
consequence, stimulation with K562 cells will lead to a decrease of
the MFI of NKG2D on degranulating cells as a result of NKG2D loss
Fig. 2. Reduced NKG2D-dependent degranulation and activation of NK cells in chronic untreated HIV-1 infection. Flow plots (A) show representative raw ﬂow cytometric data from a
single individual measuring NK cell degranulation (CD107a expression) (top) and activation (CD69 expression) (bottom) following stimulation with 221 cells (middle) and K562
cells (right). The dot plot represents the overall NK cell degranulation (CD107a) and activation (CD69) of NK cells following stimulation with 221 cells (B) or K562 (C) cells in HIV-
infected (squares) or uninfected individuals (circles). The dot plots represent the distribution of NK cell responses among the different patient subpopulations.
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determine whether increased levels of sMICA result in aberrant
NKG2D responsiveness (Groh et al., 2002), we incubated PBMCs from
healthy controls with increasing levels of sMICA and then stimulated
themwith K562 cells. Our results show a positive correlation between
sMICA and NKG2D MFI on degranulating cells after stimulation
(Fig. 4B), i.e. the higher the sMICA value of the serum the less NKG2D
is downregulated from the cell surface after activation, which
indicates that sMICA may impair NKG2D-mediated activation of NK
cells and therefore impair NK cell effector function.
Elevated transcription of NKG2DL cleaving enzymes in HIV-infected
CD4+ T cells
In the setting of MultipleMyeloma (MM),MICA is secreted from the
surface of tumor cells by the proteolytic enzyme ERP5 (Jinushi et al.,2008; Kaiser et al., 2007). In addition, MMPs have also been shown to
cleave and therefore release of MICA into the peripheral circulation
(Salih et al., 2002;Waldhauer et al., 2008). To determine which class of
enzymes may be involved in the cleavage of MICA from the surface of
HIV-1 infected CD4+ T cells, we looked at the mRNA transcriptional
level of different MMPs (including MMP 1,2,7,9) and ERP5− in HIV-1
infected and uninfected CD4+ T cells derived from infected and non-
infected individuals. QPCR analysis revealed signiﬁcantly higher
transcriptional levels of MMP-7 and a tendency to higher MMP-2 levels
in CD4+-T helper cells from infected individuals compared to the
control group (Fig. 5) potentially contributing to elevated MICA
shedding in chronic untreated patients. In contrast, no difference was
observed for MMP-1 and MMP-9 (data not shown). Furthermore, no
difference was observed in ERP5 transcript levels in puriﬁed CD4+ T
cells suggesting that this protein is likely not responsible for NKG2DL
shedding in HIV-1 infected CD4+ T cells, as it is in MM (Fig. 5). These
Fig. 3. Chronic HIV infection is associated with impaired downregulation of NKG2D-
dependent NK cell activation. Downregulation of NKG2D on CD107a+ cells was
measured in Δ percent and compared among HIV-negatives (n=10), HIV-1 infected
HAART naïve (n=10), HIV-1 infected individuals receiving HAART (n=6) and HIV
controllers (n=10) after stimulation with K562 cells (NKG2D target cell line).
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NKG2DL release into the peripheral circulation.HIV infection results in the upregulation of NKG2DLs in CD4+ T cells
To deﬁne whether HIV infection is able to induce the expression of
NKG2DLs, we ﬁrst examined whether in vitro infection of CD4+ T
cells altered NKG2DL transcription. Thus activated CD4+ T cells were
generated from 8 different HIV-negative donors, and were infected in
vitro. Following 2 days of coculture RNAwas extracted and the level of
MICA and MICB expression were quantiﬁed by qPCR and the values
were normalized to GAPDH. HIV-infected CD4+ T cells expressed
signiﬁcantly higher levels of MICA transcripts compared to matched
uninfected CD4+ T cells (p=0.003, Fig. 6A). In contrast, no change
was observed in MICB transcript levels (data not shown). These data
strongly suggest that activation of CD4+ T cells alone is not sufﬁcient
to upregulate NKG2D-ligand, but that HIV infection preferentially
induces the upregulation of MICA transcripts.Fig. 4. A. Elevated secretion of the NKG2D ligand MICA in chronic HIV-1 infection. (A) Dot
untreated (triangles, n=17), chronic treated (squares, n=16), HIV controllers (transparen
ratio of NKG2D expression on stimulated:unstimulated NK cells in the presence of increasin
capacity of NK cells to downregulate NKG2D. The dotted line represents the average NKG2Despite the upregulation of MICA transcripts, we did not observe
any change in the expression of MICA on the surface of HIV-infected
CD4+T cells (Fig. 6B). These data suggest that MICAmay either not be
translated upon transcriptional activation or that MICA proteins are
rapidly cleaved from the surface of the cell surface, due to the
upregulation of MMPs (Fig. 5). Thus to test the second hypothesis, we
blocked MMP activity using a general MMP-inhibitor GM6001. In the
absence of the MMP-inhibitor, MICA expression did not increase on
the surface of infected cells (Fig. 6B). However, in the presence of the
inhibitor, we observed a signiﬁcant upregulation of MICA expression,
that did not appear on uninfected MMP-inhibitor treated cells,
strongly suggesting that MICA expression is induced on infected
CD4+ T cells upon HIV infection. However, HIV has evolved a
mechanism to counteract this activity by upregulating MMP activity
that reduces the susceptibility of infected cells to NKG2D-mediated
elimination by rapidly eliminating its ligands.
Discussion
The quality of NK cell mediated cytotoxicity is critical for the host
immune response against infections (Biron et al., 1989; Etzioni et al.,
2005; Trinchieri, 1989). However, several features of the NK cell
response in HIV-1 infection are aberrant. These include changes in the
distribution of NK cell subsets, changes in NK cell receptor expression,
and a dramatic loss of NK cell function (Alter et al., 2005; Liu et al.,
2009; Mavilio et al., 2005; Zaunders et al., 1995), including changes in
NKG2D expression (Mavilio et al., 2003). It has been postulated that
persistent viral replication may drive these changes in NK cell
phenotype and function, however the underlying mechanisms that
accounts for this dysregulation are yet to be deﬁned. Several tumors
are able to evade NK cell detection through the release of NKG2DLs
that bind NKG2D on the surface of NK cells, thus driving them into a
refractory state (Groh et al., 2002). Here we show for the ﬁrst time
that, similar to some tumors, HIV-1 is able to evade NK cell detection
by inactivating these cells at a distance via the release of NKG2DLs
from the surface of infected cells by MMP-2 and -7. These data
elucidate a novel mechanism by which HIV-1 is able to indirectly
evade NK cells and can lead to the consequential accumulation of
dysfunctional NK cells in chronic infection.
NKG2D plays a critical role in NK cell mediated control and
clearance of a number of different infections (Biron et al., 1989;
Etzioni et al., 2005; Fang et al., 2008). We show new dataplots represent serum levels of soluble NKG2DL MICA among individuals with chronic
t circles, n=10), and HIV-negative controls (ﬁlled circles, n=9). (B) Graphs depict the
g doses of sMICA in 4 individuals, suggesting that increasing doses of sMICA reduce the
D MFI in unstimulated NK cells.
Fig. 5. Upregulation of MMP-2 and MMP-7, but not ERP5 in HIV+CD4+ T cells. Depicted bars compare transcriptional levels of proteolytic enzymes MMP-2, MMP-7, and ERP-5
between HIV positives (n=8) and the healthy control group (n=8).
17A. Nolting et al. / Virology 406 (2010) 12–20demonstrating that NKG2D expression and transcription are both
reduced in NK cells in chronic untreated HIV-1 infection compared to
spontaneous controllers. These changes in NKG2D expression were
also associated with a reduced capacity of NK cells to respond to
NKG2D-target cell lines, K562, but not other target cell lines. These
data suggest that NKG2D-dependent degranulation in NK cells may be
speciﬁcally dysfunctional in HIV-1 infection.
A number of tumors result in a profound down-modulation of
NKG2D (Groh et al., 2002; Salih et al., 2002; Wiemann et al., 2005), in
the presence of high levels of the soluble NKG2DL MICA (sMICA).
Shedding of MICA by proteolytic enzymes has been clearly associated
with disease progression in certain cancer models such as MM and
other cancer models {Jinushi, 2008 #6827}. Here we looked at the
sMICA level in the plasma of different clinical subgroups and found
sMICA to be signiﬁcantly elevated in chronic HIV-1 infection
compared to controllers and negative controls. These data indicateFig. 6. In vitro HIV infection induces NKG2D-ligand, MICA, expression on CD4+ T cells.
(A) The whisker plot depicts the relative expression of MICA transcripts: to the house
keeping geneGAPDH transcripts in vitro uninfected (circles) or infected (squares) CD4+T
cells from 4 HIV-negative donors. (B) The whisker plots represent the mean ﬂuorescence
intensity of MICA on the surface of uninfected or infected CD4+ T cells (gated on CD3+
cells) in the presence or absence of the MMP-inhibitor GM6001.that HIV-1may have evolved a mechanism to release this stress signal
from the surface of infected cells as a means to evade detection by NK
cells.
Previous work has shown that HIV-1 is able to evade NKG2D-
detection, as the Nef protein is able to downregulate some of
NKG2DLs from the surface of infected cells (Cerboni et al., 2007).
The fact that Nef has evolved this capacity strongly suggests that
NKG2D+ NK cells place sufﬁcient pressure on virally infected cells
that the virus has devised a means to circumvent this activity.
However, the downregulation of NKG2DL still does not account for the
dysregulated NK cell activity that is observed over the course of HIV-1
infection. Here we suggest that the additional release of NKG2DLs
from the surface of infected CD4+ T cells or other susceptible cells
may account for the induction of NK cell dysfunction, rendering NK
cells refractory if they come in contact with an infected cell. Thus the
persistent release of MICA, while protecting cells from direct NKG2D-
mediated recognition, may also result in a progressive accumulation
of dysfunctional NK cells over time, in line with the observed
accumulation of anergic NK cells in the peripheral blood of chronically
infected individuals. Thus, HIV-1 is able to evade NK cells in two
different manners, the downregulation of MICA from the surface of
infected cells via NEF and the shedding of MICA from the cell surface.
Previous work suggests that both MMPs and ERP5 are associated
with MICA shedding (Kaiser et al., 2007; Salih et al., 2002). Here we
did not detect any differences in ERP5 transcription among the CD4+-
T cells derived from different clinical groups of HIV-1 infected patients
compared to controls (Fig. 5). These data suggest that MMPs rather
than ERP5may be involved inMICA shedding in HIV-1-infection. Thus
inhibition of these enzymes might represent a novel therapeutic
approach to consider in the future to promote NK cell mediated
elimination of HIV-infected CD4+ T cells. This approach has already
been used successfully in a number of clinical trials that employed
synthetic inhibitors of MMPs to treat AIDS related malignancies
(Brown, 2000; Dezube et al., 2006).
In conclusion, here we show that HIV-1 may indirectly drive NK
cell exhaustion via the release of NKG2DLs into the peripheral
circulation, mediated by elevated levels of MMPs in HIV-1 infected
CD4+ T cells. This novel evasion strategy provides an additional
means bywhich HIV-1 is able to subvert detection by NK cells and also
possibly NKG2D+ T cells. New strategies aimed at inhibiting MMP
activity or blocking the binding of soluble NKG2DL may provide novel
avenues by which to improve NK cell activity, potentially allowing
them to gain enhanced control over viral replication in vivo.
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Subjects
A total of 100 subjects were recruited for this study, including 35
healthy HIV-negative control subjects, 25 untreated chronically HIV-
1-infected subjects with a median viral load of 77,000 copies/ml
(range 3310–379,251 copies/ml) and CD4+ T cell count of 448/mm3
(range 65–1041/mm3), 25 HIV-infected subjects receiving highly
active antiretroviral therapy (HAART) with a median viral load of
3079 copies/ml (range b50–17,300 copies/ml) and CD4 counts of
621/mm3 (range 192–1162/mm3), and 15 subjects that spontane-
ously controlled HIV-1 replication without antiretroviral therapy
(referred to as HIV-1 controllers) with a median viral load of 1841
copies/ml (range b50–5360 copies/ml) and CD4+ T cell count of 683
(range 169–1290/mm3). The MGH institutional review board ap-
proved the study, and each subject gave written informed consent for
participation in the study.
Cell lines
K562 and 221 cell lines were cultured in RPMI 1640 medium
supplemented with glutamine, 10% fetal calf serum, penicillin, and
streptomycin. Both cell lines are MHC class I devoid.
Flow cytometry and antibodies
Peripheral blood mononuclear cells (PBMCs) were obtained after
Ficoll–Hypaque density gradient centrifugation of whole blood. At the
same time, plasma was collected from each patient for the MICA ELISA
(below). To determine NKG2D surface expression and NK cells
responses following stimulation with different target cells (221 cells
or K562 cells), PBMCs were resuspended at 2×106/ml cells in RPMI
medium supplemented with glutamine, 10% fetal calf serum, penicillin,
and streptomycin. Ex vivo NKG2D-expression was analyzed immedi-
ately by staining PBMCs with CD3-Paciﬁc Blue, CD8-Alexa 700, CD16–
APC–Cy7, CD56–Pe–Cy-7, CD69–PE, NKG2D–APC for 20min. The cells
were then washed, resuspended in 1% paraformaldehyde (Sigma, St.
Louis, MO), and at least 5×105 cells were acquired on a Becton
Dickinson (BD) LSRII ﬂow cytometer. To gate on NK cells, we ﬁrst gated
on CD3-negative lymphocytes. Then CD56 and/or CD16-positive cells
were included in the NK cell gate. Thus NK cells included both CD56-
negativeNK cells that have been shownpreviously to accumulate inHIV
infection (Alter et al., 2005; Mavilio et al., 2005) as well as CD16-
negative CD56dim NK cells that may represent a subset of NK cells that
have recently lost CD16 following activation (Liu et al., 2009), thereby
including the largest fraction of NK cells based on known subsets.
The functional capacity of NKG2D+ NK cells was assessed
following stimulation of PBMC with either 221 or K562 target cells,
as described previously (Alter et al., 2005). Thus, PBMCs were
resuspended at 106 cells/ml in media containing CD107a–Pe–Cy5
(BD) and Golgi Stop (3 μg/ml), in the presence of either target cell line
at an effector:target ratio of 10:1, medium alone served as a negative
control. PBMCs were stimulated for 4 h at 37 °C and 5% CO2. PBMCs
were stained with CD3-Paciﬁc Blue, CD8-Alexa 700, CD16–APC–Cy7,
CD56–Pe–Cy-7, CD69–PE, NKG2D–APC (BD Biosciences, San Jose, CA)
for 20 min, washed with PBS and resuspended in 1% paraformalde-
hyde (Sigma, St. Louis, MO). All samples were acquired on a BD LSR II
(BD Biosciences, San Jose, CA). Five hundred thousand to 106 events
were acquired and analyzed using FlowJo software. NKG2D-down-
regulation following stimulation was calculated as Δ% of NKG2D
expression on responding and non-responding NK cells following
stimulation. Thus we calculated: the percent change in NKG2D
expression on CD107aneg NK cells−% changes in NKG2D expression
on the surface of CD107apos NK cells to determine the capacity of NK
cells to downregulate NKG2D following stimulation.To determine the inﬂuence of sMICA levels on NKG2D down-
regulation on NK cells after K562 stimulation, PBMCs of four HIV-1
negative control individuals were incubated for 2 h at 37° in 5% CO2 in
the presence of plasma derived from chronic untreated HIV-1 infected
individuals with different sMICA levels. After incubation, PBMCs were
stimulated with K562 as described above in the presence of Brefeldin
A (0.5 μg/ml) and stained after 4 h with CD3-Paciﬁc Blue, CD8-Alexa
700, CD16–APC–Cy7, CD56–Pe–Cy-7, NKG2D–APC (BD Biosciences,
San Jose, CA) for 20 min, washed with PBS and resuspended in 1%
paraformaldehyde (Sigma, St. Louis, MO). All samples were acquired
on a BD LSR II (BD Biosciences, San Jose, CA). 106 events were acquired
and analyzed using FlowJo software. The effect of increasing doses of
sMICA on NK cell mediated NKG2D downregulation was calculated as
the ratio of the NKG2D MFI on [stimulated/unstimulated] NK cells.
Isolation of CD4+-T cells
CD4-T cells were isolated from PBMCs derived from HIV-1 infected
patients and uninfected subjects by negative selection using MACS
human CD4+T cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach,
Germany) as instructed by the manufacturer.
NK cell isolation
NK cells were puriﬁed using the NK cell enrichment cocktail
RosetteSep (StemCell Technologies Inc., Vancouver, Canada). NK cells
were lysed for RNA puriﬁcation and subsequent cDNA synthesis, and
then used for quantitative RT-PCR.
Quantitative real time-polymerase chain reaction (q-RT-PCR)
Transcript levels of NKG2D, its ligands, and intracellular enzymes that
are able to cleave these proteins, were determined by quantitative real
time PCR. Total RNAwas isolated frompuriﬁedNK cells or isolated CD4+
T cells using the RNeasy plus KIT (Quiagen, Hilden, Germany), which
includes a genomic DNA elimination step, and reverse transcribed using
SuperScriptIII (Invitrogen, Karlsruhe, Germany) according to the man-
ufacturer's protocol. The resulting cDNA was ampliﬁed with NKG2D-,
NKG2D-ligand-orproteolytic enzymes-speciﬁcprimerpairs in duplicate.
Cycling conditions for real time PCR were: 50° for 2 min, 95° for 5 min,
95° for 30 s, 60° for 1 min, 95° for 1 min, 55° for 30 s, and 95° for 30 s. A
total of 40 cycles were performed. Ampliﬁcation was monitored using
SYBR Green Full velocity mastermix (Stratagene, Cedar Creek, TX) on a
Mxpro 3000 and 3005 qPCR cycler. Samples were normalized to GAPDH
RNA to account for the variability in the initial concentration of the total
RNA and conversion efﬁciency of the reverse transcription reaction.
Primers used were: GAPDH forward ACCCACTCCTCCACCTTTGA, reverse
TGGTGGTCCAGGGGTCTTAC; NKG2D forward CTGGGAGATGAGT-
GAATTTCATA, reverse GACTTCACCAGTTTA-AGTAAATC; MMP2 forward
CGCTCTGTCTCCTGGGCT, reverse AGGTATTG-CACTGCCAACTCTT; MMP7
forward AACTCCCGCGTCATAGAAAT, reverse GATACGATCCTGTAGGT-
GAC; ERP5 forward TGCGGCACGCTGCAGGGCT, reverse TTGACAGTGAC-
CACACCATGGAGCATA; MICA forward TTCTGG-CTGGCATCTTCCCT,
reverse TCCCATGTCTTATTTCCCA; MICB forward TTCTG-
GCCGTCGCCTTCCCT, and reverse TCCCAGGTCTCAGCTCCCA.
MICA ELISA
The commercially available MICA Elisa kit from Bamomab
(Munich, Germany) was used to quantify soluble NKG2D ligand
MICA (sMICA), as directed. Brieﬂy, plates were coated overnight with
the capture anti-MICAmAb AMO-1 at 2 μg/ml in PBS, then blocked by
addition of 100 μl of 15% BSA for 2 h at 37 °C and washed. Standards
and samples were added and the plates were incubated for 2 h at
37 °C. Plates were washed and the detection mAb BAMO-3 at 5 μg/ml
in 7.5% BSA–PBS was added for 2 h at 37 °C. Plates were then washed
19A. Nolting et al. / Virology 406 (2010) 12–20and anti-mouse IgG2a-HRP (1:8000 in 7.5% BSA–PBS) was added for
1 h at 37 °C. Plates were then washed and developed using the
Tetramethylbenzidine Peroxidase Substrate System (KPL, Gaithers-
burg, MD). The absorbance was measured at 450 nm.
MMP-inhibitor induced expression of MICA/B expression
PBMC were isolated from the peripheral blood of HIV-negative
donors and stimulated for 3 days with 0.3ug of a CD3/CD8 bispeciﬁc
antibody in the presence of 50 units of IL-2 in complete RPMI. This
culture results in the enrichment of a population of highly activated
CD4+ T cells that were subsequently infected at a multiplicity of
infection of 1 for 3 h, and then placed in culture in the presence or
absence of the MMP-inhibitor GM6001 (Gallardin, Calbiochem) for
2 days. The mean ﬂuorescence intensity of MICA/B-PE (BD Bios-
ciences) was then quantiﬁed on the surface of CD3+ T cells on a BD
LSR2. A minimum of 3×105 events were acquired and all experiments
were analyzed using FlowJo software.
Statistical analysis
Differences between groups were determined using a Mann–
Whiney U, non-parametric test, for assessing differences between
independent samples. A wilcoxon-matched pairs test was employed
to deﬁne whether differences existed between matched samples. A
Friedman test was employed to deﬁne whether differences existed
between repeated measures represented in matched observations.
Signiﬁcant differences were noted to be pb0.05.
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